Literature DB >> 23322513

Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats.

Y-Y Fan1, H Kobori, D Nakano, H Hitomi, H Mori, T Masaki, Y-X Sun, N Zhi, L Zhang, W Huang, B Zhu, P Li, A Nishiyama.   

Abstract

We have previously reported that intrarenal angiotensin II (Ang II) levels are increased long before diabetes becomes apparent in obese Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats, a model of type 2 diabetes. In this study, we examined the changes in intrarenal renin-angiotensin system (RAS) activity in the developing kidneys of OLETF rats. Ang II contents and mRNA levels of RAS components were measured in male OLETF and control Long-Evans Tokushima (LETO) rats at postnatal days (PND) 1, 5, and 15, and at 4-30 weeks of age. In both LETO and OLETF rats, kidney Ang II levels peaked at PND 1, then decreased during the pre- and post-weaning periods. However, Ang II levels and gene expression of RAS components, including angiotensinogen (AGT), renin, and angiotensin-converting enzyme (ACE), were not significantly different between LETO and OLETF rats. Intrarenal Ang IIcontents further decreased during puberty (from 7 to 11 weeks of age) in LETO rats, bur not in OLETF rats. At 11 weeks of age, kidney Ang II levels, urinary AGT excretion, and mRNA levels of AGT and renin were higher in OLETF rats than in LETO rats, while blood glucose levels were not significantly different between these groups of rats. These data indicate that continued intrarenal expression of Ang II during pubescence contributes to the increases in intrarenal Ang II levels in prediabetic OLETF rats, and is associated with increased intrarenal AGT and renin expression. Inappropriate activation of the intrarenal RAS in the prediabetic stage may facilitate the onset and development of diabetic nephropathy in later life. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322513      PMCID: PMC3655199          DOI: 10.1055/s-0032-1331256

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  21 in total

1.  Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.

Authors:  Yu-Yan Fan; Ryoko Baba; Yukiko Nagai; Akira Miyatake; Naohisa Hosomi; Shoji Kimura; Guang-Ping Sun; Masakazu Kohno; Mamoru Fujita; Youichi Abe; Akira Nishiyama
Journal:  Hypertens Res       Date:  2006-03       Impact factor: 3.872

2.  Effect of retinoic acid in experimental diabetic nephropathy.

Authors:  Sang-Youb Han; Gyeong-A So; Yi-Hwa Jee; Kum-Hyun Han; Young-Sun Kang; Hyoung-Kyu Kim; Shin-Wook Kang; Dae-Suk Han; Jee-Young Han; Dae-Ryong Cha
Journal:  Immunol Cell Biol       Date:  2004-12       Impact factor: 5.126

3.  CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells.

Authors:  Benjamin S Weston; Nadia Abdel Wahab; Roger M Mason
Journal:  J Am Soc Nephrol       Date:  2003-03       Impact factor: 10.121

4.  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.

Authors:  Yukiko Nagai; Li Yao; Hiroyuki Kobori; Kayoko Miyata; Yuri Ozawa; Akira Miyatake; Tokihito Yukimura; Takatomi Shokoji; Shoji Kimura; Hideyasu Kiyomoto; Masakazu Kohno; Youichi Abe; Akira Nishiyama
Journal:  J Am Soc Nephrol       Date:  2005-01-12       Impact factor: 10.121

5.  Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA.

Authors:  Hiroyuki Kobori; Akemi Katsurada; Kayoko Miyata; Naro Ohashi; Ryousuke Satou; Toshie Saito; Yoshiaki Hagiwara; Kazuya Miyashita; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2008-03-19

6.  Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.

Authors:  Akira Nishiyama; Toshitaka Nakagawa; Hiroyuki Kobori; Yukiko Nagai; Noriyuki Okada; Yoshio Konishi; Takashi Morikawa; Michiaki Okumura; Isseiki Meda; Hideyasu Kiyomoto; Naohisa Hosomi; Takefumi Mori; Sadayoshi Ito; Masahito Imanishi
Journal:  J Hypertens       Date:  2008-09       Impact factor: 4.844

7.  Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells.

Authors:  Denis Feliers; Balakuntalam S Kasinath
Journal:  Mol Cell Endocrinol       Date:  2009-09-16       Impact factor: 4.102

8.  Activation of a local renin angiotensin system in podocytes by glucose.

Authors:  Raghu V Durvasula; Stuart J Shankland
Journal:  Am J Physiol Renal Physiol       Date:  2008-01-23

9.  Activation of angiotensin-generating systems in the developing rat kidney.

Authors:  I V Yosipiv; S S el-Dahr
Journal:  Hypertension       Date:  1996-02       Impact factor: 10.190

10.  Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis.

Authors:  Hideki Yokoi; Masashi Mukoyama; Tetsuya Nagae; Kiyoshi Mori; Takayoshi Suganami; Kazutomo Sawai; Tetsuro Yoshioka; Masao Koshikawa; Takashi Nishida; Masaharu Takigawa; Akira Sugawara; Kazuwa Nakao
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

View more
  10 in total

1.  Urinary angiotensinogen increases in the absence of overt renal injury in high fat diet-induced type 2 diabetic mice.

Authors:  Virginia Reverte; Venkateswara R Gogulamudi; Carla B Rosales; Diego C Musial; Sabrina R Gonsalez; Alberto J Parra-Vitela; Michelle Galeas-Pena; Venkata N Sure; Bruna Visniauskas; Sarah H Lindsey; Prasad V G Katakam; Minolfa C Prieto
Journal:  J Diabetes Complications       Date:  2019-10-05       Impact factor: 2.852

Review 2.  Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.

Authors:  Bancha Satirapoj
Journal:  Kidney Dis (Basel)       Date:  2017-04-08

Review 3.  Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.

Authors:  Songyan Wang; Bing Li; Chunguang Li; Wenpeng Cui; Lining Miao
Journal:  J Diabetes Res       Date:  2015-09-02       Impact factor: 4.011

4.  Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.

Authors:  Seok Joon Shin; Sungjin Chung; Soo Jung Kim; Eun-Mi Lee; Young-Hye Yoo; Ji-Won Kim; Yu-Bae Ahn; Eun-Sook Kim; Sung-Dae Moon; Myung-Jun Kim; Seung-Hyun Ko
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

Review 5.  Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.

Authors:  Tuba M Ansary; Daisuke Nakano; Akira Nishiyama
Journal:  Int J Mol Sci       Date:  2019-02-01       Impact factor: 5.923

6.  Characteristics of aldosterone-producing adenomas in patients without plasma renin activity suppression.

Authors:  Haremaru Kubo; Yuya Tsurutani; Kosuke Inoue; Kazuki Watanabe; Yuto Yamazaki; Takashi Sunouchi; Yoshitomo Hoshino; Rei Hirose; Sho Katsuragawa; Hiromitsu Tannai; Yukiko Shibahara; Yukio Kakuta; Seishi Matsui; Jun Saito; Masao Omura; Hironobu Sasano; Tetsuo Nishikawa
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.240

7.  Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.

Authors:  Yutaka Mori; Shizuka Aritomi; Kazumi Niinuma; Tarou Nakamura; Kenichi Matsuura; Junichi Yokoyama; Kazunori Utsunomiya
Journal:  Drug Des Devel Ther       Date:  2014-06-17       Impact factor: 4.162

Review 8.  Independent regulation of renin-angiotensin-aldosterone system in the kidney.

Authors:  Akira Nishiyama; Hiroyuki Kobori
Journal:  Clin Exp Nephrol       Date:  2018-03-29       Impact factor: 2.801

Review 9.  Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.

Authors:  Yi-Chou Hou; Cai-Mei Zheng; Tzung-Hai Yen; Kuo-Cheng Lu
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

10.  Sex differences in soluble prorenin receptor in patients with type 2 diabetes.

Authors:  Bruna Visniauskas; Danielle Y Arita; Carla B Rosales; Mohammed A Feroz; Christina Luffman; Michael J Accavitti; Gabrielle Dawkins; Jennifer Hong; Andrew C Curnow; Tina K Thethi; John J Lefante; Edgar A Jaimes; Franck Mauvais-Jarvis; Vivian A Fonseca; Minolfa C Prieto
Journal:  Biol Sex Differ       Date:  2021-05-01       Impact factor: 5.027

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.